William Blair analyst Max Smock initiates coverage on Cencora Inc (NYSE: COR) with a Market Perform rating.

The analyst comments "Scaled pharmaceutical distribution platform underpins wide competitive moat and drives high-growth specialty upside. As one of the largest global pharmaceutical distributors, Cencora is positioned to capitalize on a structurally favorable demand backdrop supported by demographic tailwinds, continued innovation and new drug launches, and rising adoption of specialty medicines."

For an analyst ratings summary and ratings history on Cencora Inc click here. For more ratings news on Cencora Inc click here.

Shares of Cencora Inc closed at $310.16 yesterday.